950 related articles for article (PubMed ID: 21190834)
21. Maximum a posteriori Bayesian estimation of mycophenolic Acid area under the concentration-time curve: is this clinically useful for dosage prediction yet?
Staatz CE; Tett SE
Clin Pharmacokinet; 2011 Dec; 50(12):759-72. PubMed ID: 22087863
[TBL] [Abstract][Full Text] [Related]
22. Clinical pharmacokinetics of mycophenolate mofetil.
Bullingham RE; Nicholls AJ; Kamm BR
Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
[TBL] [Abstract][Full Text] [Related]
23. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil.
Tedesco-Silva H; Bastien MC; Choi L; Felipe C; Campestrini J; Picard F; Schmouder R
Transplant Proc; 2005 Mar; 37(2):852-5. PubMed ID: 15848554
[TBL] [Abstract][Full Text] [Related]
24. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil.
Sánchez Fructuoso A; Calvo N; Moreno MA; Giorgi M; Conesa J; Barrientos A
Transplant Proc; 2007 Sep; 39(7):2194-6. PubMed ID: 17889135
[TBL] [Abstract][Full Text] [Related]
25. Which is more suitable for kidney transplantation at the early post-transplantation phase in China - low dosing or standard dosing of enteric-coated mycophenolate sodium?
Ding C; Xue W; Tian P; Ding X; Pan X; Xiang H; Tian X; Li Y; Zheng J
Int J Clin Pract Suppl; 2014 Apr; (181):10-6. PubMed ID: 24673714
[TBL] [Abstract][Full Text] [Related]
26. Randomized crossover study to assess the inter- and intrasubject variability of morning mycophenolic acid concentrations from enteric-coated mycophenolate sodium and mycophenolate mofetil in stable renal transplant recipients.
Tedesco-Silva H; Felipe CR; Park SI; Pinheiro-Machado PG; Garcia R; Slade A; Schmouder R; Medina-Pestana JO
Clin Transplant; 2010; 24(4):E116-23. PubMed ID: 20047618
[TBL] [Abstract][Full Text] [Related]
27. EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects.
Sabbatini M; Capone D; Gallo R; Pisani A; Polichetti G; Tarantino G; Gentile A; Rotaia E; Federico S
Fundam Clin Pharmacol; 2009 Oct; 23(5):617-24. PubMed ID: 19656208
[TBL] [Abstract][Full Text] [Related]
28. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
[TBL] [Abstract][Full Text] [Related]
29. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.
Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
Clin Chem; 2001 Jan; 47(1):88-94. PubMed ID: 11148182
[TBL] [Abstract][Full Text] [Related]
30. Limited sampling strategies drawn within 3 hours postdose poorly predict mycophenolic acid area-under-the-curve after enteric-coated mycophenolate sodium.
de Winter BC; van Gelder T; Mathot RA; Glander P; Tedesco-Silva H; Hilbrands L; Budde K; van Hest RM
Ther Drug Monit; 2009 Oct; 31(5):585-91. PubMed ID: 19704401
[TBL] [Abstract][Full Text] [Related]
31. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation.
Langone A; Shihab F; Pankewycz O; Doria C; Wiland A; McCague K; Chan L
Clin Transplant; 2014 Sep; 28(9):961-7. PubMed ID: 24893821
[TBL] [Abstract][Full Text] [Related]
32. Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis.
Salvadori M; Bertoni E; Budde K; Holzer H; Civati G; Lien B; Arns W
Transplant Proc; 2010 May; 42(4):1325-8. PubMed ID: 20534293
[TBL] [Abstract][Full Text] [Related]
33. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring?
Cox VC; Ensom MH
Ther Drug Monit; 2003 Apr; 25(2):137-57. PubMed ID: 12657908
[TBL] [Abstract][Full Text] [Related]
34. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients.
Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
J Clin Pharmacol; 2003 Aug; 43(8):866-80. PubMed ID: 12953344
[TBL] [Abstract][Full Text] [Related]
35. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation.
Tönshoff B; David-Neto E; Ettenger R; Filler G; van Gelder T; Goebel J; Kuypers DR; Tsai E; Vinks AA; Weber LT; Zimmerhackl LB
Transplant Rev (Orlando); 2011 Apr; 25(2):78-89. PubMed ID: 21454065
[TBL] [Abstract][Full Text] [Related]
36. Population Pharmacokinetics and Bayesian Estimation of Mycophenolic Acid Exposure in Chinese Renal Allograft Recipients After Administration of EC-MPS.
Chen B; Shao K; An HM; Shi HQ; Lu JQ; Zhai XH; Liu XX; Wang XH; Xu D; Zhou PJ
J Clin Pharmacol; 2019 Apr; 59(4):578-589. PubMed ID: 30537048
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients.
Nashan B; Saliba F; Durand F; Barcéna R; Herrero JI; Mentha G; Neuhaus P; Bowles M; Patch D; Bernardos A; Klempnauer J; Bouw R; Ives J; Mamelok R; McKay D; Truman M; Marotta P
Liver Transpl; 2009 Feb; 15(2):136-47. PubMed ID: 19177449
[TBL] [Abstract][Full Text] [Related]
38. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients.
Kuypers DR; Ekberg H; Grinyó J; Nashan B; Vincenti F; Snell P; Mamelok RD; Bouw RM
Clin Pharmacokinet; 2009; 48(5):329-41. PubMed ID: 19566116
[TBL] [Abstract][Full Text] [Related]
39. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease.
de Winter BC; Mathot RA; Sombogaard F; Neumann I; van Hest RM; Doorduijn JK; van Gelder T
Ther Drug Monit; 2010 Oct; 32(5):606-14. PubMed ID: 20720518
[TBL] [Abstract][Full Text] [Related]
40. The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients.
Kofler S; Wolf C; Shvets N; Sisic Z; Müller T; Behr J; Sohn HY; Vogeser M; Shipkova M; Meiser B; Steinbeck G; Reichart B; Kaczmarek I
J Heart Lung Transplant; 2011 May; 30(5):565-71. PubMed ID: 21256049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
